Achilles Therapeutics plc Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Achilles Therapeutics plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2022 to Q2 2024.
  • Achilles Therapeutics plc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $1.31M, a 22.9% decline year-over-year.
  • Achilles Therapeutics plc annual Share-based Payment Arrangement, Expense for 2023 was $6.36M, a 9.47% decline from 2022.
  • Achilles Therapeutics plc annual Share-based Payment Arrangement, Expense for 2022 was $7.02M, a 11.2% increase from 2021.
  • Achilles Therapeutics plc annual Share-based Payment Arrangement, Expense for 2021 was $6.32M, a 111% increase from 2020.
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.31M -$389K -22.9% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-14
Q2 2023 $1.7M -$23K -1.33% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-14
Q2 2022 $1.72M Apr 1, 2022 Jun 30, 2022 6-K 2023-08-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.